ANAVEX 2-73

Drug Profile

ANAVEX 2-73

Alternative Names: ANAVEX-2-73

Latest Information Update: 03 Feb 2017

Price : $50

At a glance

  • Originator Anavex Life Sciences
  • Developer ABX-CRO; Anavex Life Sciences
  • Class Antidementias; Dimethylamines; Furans; Neuroprotectants; Small molecules
  • Mechanism of Action Calcium channel antagonists; Chloride channel modulators; Muscarinic M1 receptor agonists; Muscarinic M2 receptor antagonists; Muscarinic M3 receptor antagonists; NMDA receptor antagonists; Sigma-1 receptor agonists; Sodium channel antagonists; Sodium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epilepsy; Rett syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Phase I Cognition disorders; Epilepsy; Rett syndrome
  • Preclinical Amyotrophic lateral sclerosis; Anxiety disorders; Autistic disorder; Fragile X syndrome; Multiple sclerosis; Parkinson's disease; Stroke

Most Recent Events

  • 01 Jan 2017 Anavex Life Sciences completes a phase IIa trial for Alzheimer's disease in Australia
  • 08 Dec 2016 Updated 12-month efficacy and adverse events data from a phase IIa trial in Alzheimer’s disease released by Anavex Life Sciences
  • 23 Nov 2016 Updated efficacy and adverse event data from a phase IIa trial in Alzheimer’s Disease released by Anavex Life Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top